HCA Healthcare, Inc. $HCA Shares Bought by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management raised its stake in HCA by 21.2% in Q4 to 20,692 shares valued at $9.66 million, and several other institutions also boosted positions, leaving institutional ownership at 62.73%.
• HCA beat quarterly EPS estimates with $8.01 vs. $7.37 expected while reporting $19.51 billion in revenue (up 6.7% YoY but slightly below estimates) and issuing FY2026 EPS guidance of 29.10–31.50.
• Insiders sold 15,214 shares worth about $7.8 million in the past three months (including EVP Michael McAlevey and SVP Christopher Wyatt); corporate insiders now hold 1.50% of the stock.

Robeco Institutional Asset Management B.V. raised its holdings in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 21.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,692 shares of the company's stock after purchasing an additional 3,625 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in HCA Healthcare were worth $9,660,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of HCA. Ritholtz Wealth Management boosted its holdings in shares of HCA Healthcare by 14.8% in the fourth quarter. Ritholtz Wealth Management now owns 11,976 shares of the company's stock valued at $5,591,000 after acquiring an additional 1,540 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in shares of HCA Healthcare by 10.9% in the fourth quarter. Venturi Wealth Management LLC now owns 5,204 shares of the company's stock valued at $2,429,000 after acquiring an additional 510 shares in the last quarter. Premier Path Wealth Partners LLC boosted its holdings in shares of HCA Healthcare by 9.1% in the fourth quarter. Premier Path Wealth Partners LLC now owns 1,954 shares of the company's stock valued at $912,000 after acquiring an additional 163 shares in the last quarter. Curran Financial Partners LLC purchased a new stake in shares of HCA Healthcare in the fourth quarter valued at about $342,000. Finally, True North Advisors LLC boosted its holdings in shares of HCA Healthcare by 16.9% in the fourth quarter. True North Advisors LLC now owns 1,461 shares of the company's stock valued at $682,000 after acquiring an additional 211 shares in the last quarter. 62.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Michael R. Mcalevey sold 1,694 shares of the business's stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $533.37, for a total value of $903,528.78. Following the completion of the transaction, the executive vice president owned 8,853 shares of the company's stock, valued at $4,721,924.61. The trade was a 16.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Christopher F. Wyatt sold 4,000 shares of the company's stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $505.00, for a total transaction of $2,020,000.00. Following the transaction, the senior vice president directly owned 44,379 shares of the company's stock, valued at $22,411,395. This trade represents a 8.27% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 15,214 shares of company stock worth $7,797,595. Corporate insiders own 1.50% of the company's stock.

HCA Healthcare Price Performance

NYSE:HCA opened at $489.00 on Thursday. The firm has a 50 day simple moving average of $511.89 and a 200-day simple moving average of $483.30. The firm has a market cap of $109.33 billion, a PE ratio of 17.23, a P/E/G ratio of 1.53 and a beta of 1.36. HCA Healthcare, Inc. has a 1-year low of $314.43 and a 1-year high of $556.52.

HCA Healthcare (NYSE:HCA - Get Free Report) last posted its quarterly earnings data on Tuesday, January 27th. The company reported $8.01 earnings per share for the quarter, beating analysts' consensus estimates of $7.37 by $0.64. The business had revenue of $19.51 billion during the quarter, compared to analyst estimates of $19.67 billion. HCA Healthcare had a net margin of 8.97% and a negative return on equity of 409.11%. The company's revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.22 earnings per share. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, sell-side analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 17th were given a $0.78 dividend. This is a boost from HCA Healthcare's previous quarterly dividend of $0.72. This represents a $3.12 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Tuesday, March 17th. HCA Healthcare's dividend payout ratio (DPR) is presently 10.99%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. The Goldman Sachs Group lifted their target price on shares of HCA Healthcare from $520.00 to $558.00 and gave the company a "buy" rating in a report on Wednesday, January 28th. Argus boosted their price objective on shares of HCA Healthcare from $530.00 to $560.00 and gave the stock a "buy" rating in a report on Friday, February 6th. Wells Fargo & Company boosted their price objective on shares of HCA Healthcare from $452.00 to $481.00 and gave the stock an "equal weight" rating in a report on Friday, January 30th. Cantor Fitzgerald reissued an "overweight" rating on shares of HCA Healthcare in a report on Wednesday, March 4th. Finally, UBS Group boosted their price objective on shares of HCA Healthcare from $598.00 to $635.00 and gave the stock a "buy" rating in a report on Monday, February 23rd. Sixteen equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, HCA Healthcare presently has an average rating of "Moderate Buy" and a consensus target price of $537.36.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company's core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA's services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.